Research Progress on the Influence of ABO Blood Group on Venous Thromboembolism in Cancer Patients

doi:10.3969/j.issn.1671-2587.2023.06.025

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2023, Vol. 25 ›› Issue (6): 857-861.DOI: 10.3969/j.issn.1671-2587.2023.06.025

Research Progress on the Influence of ABO Blood Group on Venous Thromboembolism in Cancer Patients

YOU Laiwei, CHENG Yong, GUO Jianrong

Department of Anesthesiology, Gongli Hospital, Naval Military Medical University, Shanghai 200135

Received:2023-09-26 Online:2023-12-20 Published:2024-01-15

Abstract

Abstract: ABO blood group is an independent risk factor for venous thromboembolism （VTE）in cancer patients. However, the specific mechanism and risk factors of ABO blood group on VTE in tumor patients are still unclear, which brings challenges to the prevention and treatment of the disease. This article deeply reviews the influence of ABO blood type on VTE in cancer patients based on the latest literature, so as to further optimize the management of VTE in cancer patients.

Key words: ABO blood group, Venous thromboembolism, Cancer patients

CLC Number:

R457

YOU Laiwei, CHENG Yong, GUO Jianrong. Research Progress on the Influence of ABO Blood Group on Venous Thromboembolism in Cancer Patients[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 857-861.

References

[1] SØRENSEN H T,MELLEMKJÆR L,OLSEN J H,et al.Prognosis of cancers associated with venous thromboembolism[J].N Engl J Med,2000,343(25):1846-1850.
[2] MULDER F I,HORVÁTH-PUHÓ E,VAN ES N,et al.Venous thromboembolism in cancer patients:a population-based cohort study[J].Blood,2021,137(14):1959-1969.
[3] GRILZ E,POSCH F,NOPP S,et al.Relative risk of arterial and venous thromboembolism in persons with cancer vs.persons without cancer-a nationwide analysis[J].Eur Heart J,2021,42(23):2299-2307.
[4] LYMAN G H,CARRIER M,AY C,et al.American Society of Hematology 2021 guidelines for management of venous thromboembolism:prevention and treatment in patients with cancer[J].Blood Adv,2021,5(4):927-974.
[5] KEY N S,KHORANA A A,KUDERER N M,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:ASCO clinical practice guideline update[J].J Clin Oncol,2020,38(5):496-520.
[6] MÉAN M,LIMACHER A,ALATRI A,et al.Derivation and validation of a prediction model for risk stratification of post-thrombotic syndrome in elderly patients with a first deep vein thrombosis[J].Thromb Haemost,2018,118(8):1419-1427.
[7] ANSTEE D J.The relationship between blood groups and disease[J].Blood,2010,115(23):4635-4643.
[8] TROUSSEAU A.Clinical lectures on medicine delivered at the Hôtel-dieu,Paris[J].Br Foreign Med Chir Rev,1862,29(58):427-435.
[9] ISTH Steering Committee for World Thrombosis Day.Thrombosis: a major contributor to the global disease burden[J].J Thromb Haemost,2014, 12(10):1580-1590.
[10] 付荣凤,薛峰.2022 ITAC国际临床实践指南:癌症(包括合并新冠肺炎患者)相关静脉血栓栓塞症的治疗和预防解读[J].血栓与止血学,2023,29(2):57-66.
[11] GRILZ E,POSCH F,NOPP S,et al.Relative risk of arterial and venous thromboembolism in persons with cancer vs.persons without cancer-a nationwide analysis[J].Eur Heart J,2021,42(23):2299-2307.
[12] KÖNIGSBRÜGGE O,PABINGER I,AY C.Risk factors for venous thromboembolism in cancer:novel findings from the Vienna Cancer and Thrombosis Study (CATS)[J].Thromb Res,2014,133(Suppl 2):S39-S43.
[13] MORANGE P E,TREGOUET D A.Lessons from genome-wide association studies in venous thrombosis[J].J Thromb Haemost,2011,9:258-264.
[14] VASAN S K,ROSTGAARD K,MAJEED A,et al.ABO blood group and risk of thromboembolic and arterial disease:a study of 1.5 million blood donors[J].Circulation,2016,133(15):1449-1457.
[15] ENGLISCH C,MOIK F,NOPP S,et al.ABO blood group type and risk of venous thromboembolism in patients with cancer[J].Blood Adv,2022,6(24):6274-6281.
[16] SUN X J,AI L,FENG Y.The value of ABO blood group and complete blood count for the prognosis analysis of gastric cancer patients[J].OncoTargets Ther,2020,13:4627-4633.
[17] TANAKA Y,KUMAGI T,TERAO T,et al.ABO blood type and the long-term outcomes of pancreatic cancer[J].Intern Med,2020,59(6):761-768.
[18] 黄彬亮,谢钊敏,王丹,等.广东潮汕地区恶性肿瘤与ABO血型的相关性分析[J].中国输血杂志,2023,36(3):254-257.
[19] COLONNE C K,FAVALORO E J,PASALIC L.The intriguing connections between von willebrand factor,ADAMTS13 and cancer[J].Healthcare,2022,10(3):557.
[20] SCHEINER B,NORTHUP P G,GRUBER A B,et al.The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease[J].Liver Int,2020,40(6):1415-1426.
[21] PARÉ G,CHASMAN D I,KELLOGG M,et al.Novel association of ABO histo-blood group antigen with soluble ICAM-1:results of a genome-wide association study of 6,578 women[J].PLoS Genet,2008,4(7):e1000118.
[22] QIN L,GAO D L,WANG Q A,et al.ABO blood group and the risk and prognosis of lymphoma[J].J Inflamm Res,2023,16:769-778.
[23] KOMINATO Y,HATA Y,TAKIZAWA H,et al.Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region[J].J Biol Chem,1999,274(52):37240-37250.
[24] CANONICO M E,SANTORO C,AVVEDIMENTO M,et al.Venous thromboembolism and cancer:a comprehensive review from pathophysiology to novel treatment[J].Biomolecules,2022,12(2):259.
[25] KAŹMIERCZAK M,LEWANDOWSKI K,WOJTUKIEWI
CZ M Z,et al.Cancer procoagulant in patients with adenocarcinomas[J].Blood Coagulation Fibrinolysis,2005,16(8):543-547.
[26] KIREEV D,POPENKO N,PICHUGIN A,et al.Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets[J].Thromb Haemost,2007,97(3):425-434.
[27] MANLY D A,WANG J G,GLOVER S L,et al.Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism[J].Thromb Res,2010,125(6):511-512.
[28] BERNARDO A,BALL C,NOLASCO L,et al.Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow[J].Blood,2004,104(1):100-106.
[29] VON BRÜHL M L,STARK K,STEINHART A,et al.Monocytes,neutrophils,and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo[J].J Exp Med,2012,209(4):819-835.
[30] CAO W,ZHU M Y,LEE S H,et al.Modulation of cellular NAD+ attenuates cancer-associated hypercoagulability and thrombosis via the inhibition of tissue factor and formation of neutrophil extracellular traps[J].Int J Mol Sci,2021,22(21):12085.
[31] XU Y X,CHEN C,GUO Y X,et al.Effect of CRISPR/Cas9-edited PD-1/PD-L1 on tumor immunity and immunotherapy[J].Front Immunol,2022,13:848327.
[32] SODETZ J M,PAULSON J C,MCKEE P A.Carbohydrate composition and identification of blood group A,B,and H oligosaccharide structures on human Factor VIII/von Willebrand factor[J].J Biol Chem,1979,254(21):10754-10760.
[33] ZHU D,LU Y,WANG Y M,et al.PAD4 and its inhibitors in cancer progression and prognosis[J].Pharmaceutics,2022,14(11):2414.
[34] DUNNE E,QI Q M,SHAQFEH E S,et al.Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function[J].Blood,2019,133(12):1371-1377.
[35] 李观强,吴凡,韦利,等.ABO血型与深静脉血栓发生风险关系的病例对照研究及Meta分析[J].中国普通外科杂志,2020,29(6):677-685.
[36] CHEN H W,WU W T,WANG J H,et al.The risk of venous thromboembolism after thoracolumbar spine surgery:a population-based cohort study[J].J Clin Med,2023,12(2):613.
[37] COUTURAUD F,MAHÉ I,SCHMIDT J,et al.Adult breast,lung,pancreatic,upper and lower gastrointestinal cancer patients with hospitalized venous thromboembolism in the national French hospital discharge database[J].BMC Cancer,2023,23(1):531.
[38] DICKMANN B,AHLBRECHT J,AY C,et al.Regional lymph node metastases are a strong risk factor for venous thromboembolism:results from the Vienna Cancer and Thrombosis Study[J].Haematologica,2013,98(8):1309-1314.
[39] KHORANA A A,DALAL M,LIN J,et al.Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States[J].Cancer,2013,119(3):648-655.
[40] BAGOLY Z.ABO blood group type and the risk of venous thromboembolism:the impact of interactions[J].Pol Arch Intern Med,2022,132(12):16378.
[41] MAJI D,NAYAK L,MARTIN J E,et al.A novel,point-of-care,whole‐blood assay utilizing dielectric spectroscopy is sensitive to coagulation factor replacement therapy in haemophilia A patients[J].Haemophilia,2019,25:885-892.
[42] FOLSOM A R,BASU S,HONG C P,et al.Reasons for differences in the incidence of venous thromboembolism in black versus white Americans[J].Am J Med,2019,132(8):970-976.
[43] CRONIN-FENTON D P,SØNDERGAARD F,PEDERSEN L A,et al.Hospitalisation for venous thromboembolism in cancer patients and the general population:a population-based cohort study in Denmark,1997-2006[J].Br J Cancer,2010,103(7):947-953.
[44] MOIK F,CHAN W S E,WIEDEMANN S,et al.Incidence,risk factors,and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy[J].Blood,2021,137(12):1669-1678.

Research Progress on the Influence of ABO Blood Group on Venous Thromboembolism in Cancer Patients

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	YANG Xuexin, WEI Yaming. The Current Situation and Suggestions of ABO-mismatched Platelet Transfusions [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 17-22.
[2]	YANG Xuexin, YUAN Yongmei, WU Zhaoyong, YUAN Zhaohu, LIU Zhen, TONG Xinxin, CHEN Xiaowei, WEI Yaming. The Preliminary Analysis of the Effectiveness and Safety of Minor ABO Incompatible Platelet Transfusions [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 42-48.
[3]	ZHUO Hailong, SHAO Chunyan, LUO qun. Effect of Mixed Red Blood Cells with Different Proportions of Type A/O on Blood Group Antigen Identification [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 475-479.
[4]	ZHAO Lizhe, LI Jianping, LI Xiaofeng. The Relationship between Gut Microbiota and Human ABO Blood Group System [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 297-301.
[5]	XIE Hui-yi, ZHOU Zai-xin, YANG Yue, et al. Analysis of the Influence of Anti-M Antibody on Blood Group Identification and Clinical Blood Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 716-720.
[6]	LI Zhi-qiang, LV Xian-ping, LIU Tie-mei, et al. A Prospective Multi-center Study on the Relationship between the Age and the Agglutination Intensity of Anti-A/B Antibody in Infants within One Year of Age [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(4): 450-454.
[7]	ZHANG Yuan-qin, WANG Mei-ru, XU Lu, et al. Study of Capillary Ultracentrifugation Technique on Prediction of Massive Maternal Transfusion Syndrome in Vitro [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(3): 301-305.
[8]	ZENG Yi-mei, LEI Hang, WANG Yu-qin, et al. ABx Subtype Formation by 1,3-D-Galactosyltransferase p.Arg187Cys Mutation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(1): 41-45.
[9]	MA Chun-ya, SUN Xiao-lin, FENG yan-nan, et al. Analysis of Influence Factors of Erythrocyte Transfusion in Patients with Hematopoietic Stem Cell Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(4): 341-344.
[10]	YU Ying, WANG Zhe-jiong, ZHU Lin-chao, et al. A Clinical Investigation of Matched Blood Transfusion in the Patients with Stem Cell Transplants of ABO Incompatibility [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2017, 19(4): 352-354.
[11]	ZHAO Ling-jun. A Case Report of Forward/Reverse Blood Grouping Discrepancy Resulting from ABO Gene Variant [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2017, 19(2): 178-182.
[12]	FANG Le, XIAO Jian-yu, WU Min-hui, et al. Identification of Serologic and Molecular Bases of B(A)04 Subtype of ABO Blood Group [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2016, 18(5): 424-427.